Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TEAD1 | P28347 | 1/20 | 0.39 |
| ▸ | ROCK2 | O75116 | 2/20 | 0.38 |
| ▸ | JAK2 | O60674 | 4/20 | 0.38 |
| ▸ | JAK3 | P52333 | 4/20 | 0.38 |
| ▸ | JAK1 | P23458 | 4/20 | 0.38 |
| ▸ | TYK2 | P29597 | 2/20 | 0.38 |
| ▸ | CCR3 | P51677 | 3/20 | 0.38 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.38 |
| ▸ | DRD2 | P14416 | 2/20 | 0.37 |
| ▸ | DRD4 | P21917 | 2/20 | 0.37 |
| ▸ | CCR2 | P41597 | 1/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | MCHR2 | Q969V1 | 1/20 | 0.36 |
| ▸ | GRM2 | Q14416 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14824 | 0.95 | ROCK2 (0.44) | ROCK2JAK2JAK3MCHR1CCR2 | |
| SCHEMBL17277305 | 0.85 | ROCK2 (0.40) | TEAD1ROCK2CCR3MCHR1DRD2 | |
| SCHEMBL12075449 | 0.83 | CCR2 (0.39) | TEAD1ROCK2CCR3MCHR1DRD2 | |
| SCHEMBL12062170 | 0.83 | ROCK2 (0.39) | TEAD1ROCK2CCR3MCHR1CCR2 | |
| SCHEMBL17277490 | 0.80 | ROCK2 (0.46) | ROCK2CCR2 | |
| SCHEMBL14830 | 0.80 | PRKACA (0.43) | ROCK2JAK2JAK3JAK1TYK2 | |
| SCHEMBL12075870 | 0.78 | ROCK2 (0.45) | ROCK2CCR2 | |
| SCHEMBL12075462 | 0.78 | ROCK2 (0.44) | ROCK2MCHR1CCR2 | |
| SCHEMBL20082562 | 0.75 | ADORA2B (0.42) | CCR3 | |
| SCHEMBL14773 | 0.72 | ROCK2 (0.33) | TEAD1ROCK2CCR3DRD2GRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | BioVersys AG (CH) | 2016-02-04 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-9193731-B2 | Antimicrobial compounds and methods of making and using the same | MELINTA THERAPEUTICS, INC. (US) | 2015-11-24 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | RIB-X PHARMACEUTICALS, INC. (US) | 2012-08-30 | — | — | US | disclosed |
| WO-2011047319-A2 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | RIB-X PHARMACEUTICALS, INC. (US) | 2011-04-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120220566-A1 | Antimicrobial Compounds and Methods of Making and Using the Same | MPO, LPO, CAT | TEAD1 2100/4885ROCK2 3307/4885JAK2 3797/4885 |
| US-20160031893-A1 | ANTIMICROBIAL COMPOUNDS AND METHODS OF MAKING AND USING THE SAME | MPO, LPO, CAT | TEAD1 2100/4885ROCK2 3307/4885JAK2 3797/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.